InterMune Announces 6.5M Share Offering
InterMune (NASDAQ: ITMN) today announced that it plans to offer, subject to market and other conditions, 6,500,000 shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock in connection with the offering. All of the shares in the offering will be sold by InterMune. The shares will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and Exchange Commission (SEC) on Form S-3.
InterMune intends to use the net proceeds from the offering to fund the commercialization of Esbriet® (pirfenidone) and its ASCEND clinical trial for U.S. registration of Esbriet, to advance the company's strategic initiatives including its new Esbriet formulations, its recently launched clinical trials supporting the use of Esbriet in idiopathic pulmonary fibrosis (IPF) and in potential new indications, its expanding anti-fibrotic research program with compounds intended to address IPF and other fibrotic diseases, and for general corporate purposes.
Goldman, Sachs & Co. and J. P. Morgan Securities LLC are acting as joint book-running managers of the proposed offering.